Pelthos Therapeutics Inc. Shareholders' Equity
Pelthos Therapeutics Inc. (PTHS) had Shareholders' Equity of -$1.50 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent -$1.50M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $19.27M; Stockholders' Equity Attributable to Parent as first filed $35.10M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $38.88M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $58.25M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$1.50M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $19.27M 10-Q/A · filed 2026-08-13 | $35.10M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $38.88M 10-Q/A · filed 2026-08-13 | |
| 2025-09-30 | $58.25M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$6.50M 10-Q · filed 2026-08-13 | -$6.49M 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$4.20M 10-Q/A · filed 2026-08-13 | -$4.20M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$2.71M 10-Q/A · filed 2026-08-13 | -$2.71M 10-K · filed 2025-03-27 |
| 2024-09-30 | -$1.43M 10-Q · filed 2025-11-13 | -$1.43M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$184.00K 10-Q · filed 2025-11-13 | -$182.52K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.13M 10-Q · filed 2025-11-13 | $1.13M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$6.45M 10-K · filed 2026-03-19 | -$6.44M 10-K · filed 2024-04-16 |
| 2023-09-30 | -$5.90M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$4.90M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | -$4.44M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | -$3.71M 10-K · filed 2025-03-27 | |
| 2021-12-31 | -$3.68M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |